BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 35190335)

  • 21. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
    Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
    Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].
    Heidegger I; Becker C; Tsaur I; Todenhöfer T;
    Urologe A; 2022 Feb; 61(2):187-192. PubMed ID: 35013792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Xu C; Mao S; Jiang H
    Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
    Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer and PARP inhibitors: progress and challenges.
    Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
    J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research progress on the treatment of advanced prostate cancer with Olaparib.
    Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
    Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.
    Fan Y; Liu Z; Chen Y; He Z
    Adv Ther; 2024 Jun; 41(6):2196-2216. PubMed ID: 38767824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
    Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
    Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current therapy and drug resistance in metastatic castration-resistant prostate cancer.
    Cai M; Song XL; Li XA; Chen M; Guo J; Yang DH; Chen Z; Zhao SC
    Drug Resist Updat; 2023 May; 68():100962. PubMed ID: 37068396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
    Higano CS; Cheng HH
    Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
    Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
    Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
    Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
    Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
    Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.